Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-19

Clinical Trial Update: Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 efficacy trial assessing a combination of sorafenib and cyclophosphamide in patients with neuroendocrine tumors. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CYCLOPHOSPHAMIDE (Cyclophosphamide)
  • Sorafenib (Sorafenib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2019-02-19